Key Highlights

  • Elevance's $1.72 quarterly Dividend trades ex-date September 10, 2026, payable September 25, yielding approximately 1.71%.
  • Second-quarter adjusted EPS of $7.45 beat expectations but included an approximately $0.80 per share net below-the-line benefit; excluding that, adjusted EPS actually declined 15.7% year over year.
  • Medical membership fell to 44.9 million, down sequentially due to commercial fee-based transitions and anticipated ACA and Medicaid attrition.
  • The company raised full-year adjusted EPS guidance to at least $27.00 and reiterated a target of returning to 12% adjusted EPS growth in 2027.

Elevance Health's (NYSE:ELV) $1.72 quarterly dividend yields approximately 1.71%, a payout that looks well-covered on the surface but sits atop a quarter with a more complicated Earnings picture than the headline beat suggests. The real story is that adjusted EPS of $7.45, while ahead of expectations, included a roughly $0.80 per share one-time investment-related benefit; stripped of that, underlying adjusted EPS actually fell 15.7% from a year earlier, a decline investors should weigh more heavily than the reported beat.

Dividend Program and Shareholder Returns

Elevance declared a third-quarter 2026 dividend of $1.72 per share on July 14, 2026, payable September 25 to shareholders of record September 10. At the current quarterly rate, that represents $6.88 per share annualized. The company's filings state that dividends and repurchases remain subject to Board consideration of financial condition, Liquidity needs and regulatory Capital requirements, an important qualifier given the underlying earnings softness this quarter.

About the Company

Elevance Health is a major U.S. health benefits company combining risk-bearing insurance operations across commercial, Medicaid and Medicare Advantage populations with Carelon, its pharmacy, behavioral health and care-delivery services arm. This combination gives Elevance both premium-based insurance exposure and fee- or service-based Revenue streams.

Financial Performance Behind the Payout

Elevance reported second-quarter Operating Revenue of $49.8 billion, up 0.8% year over year, driven by higher premium yields in Health Benefits and CarelonRx product growth, partly offset by anticipated membership declines. GAAP diluted EPS was $6.71 and adjusted diluted EPS was $7.45, but management explicitly attributed roughly $0.80 per share of that figure to a net below-the-line benefit from investment-related valuation adjustments; comparably, adjusted EPS was $8.84 in the year-ago quarter, meaning the underlying trend is a 15.7% decline once the one-time item is excluded. The benefit expense ratio rose 80 basis points to 89.7%, driven by elevated medical cost trend in government businesses. Medical membership fell to 44.9 million, down 469,000 sequentially.

A Beat That Isn't What It Appears

Elevance's headline adjusted EPS beat obscures a genuine year-over-year earnings decline once the one-time Investment benefit is excluded, making this a quarter where the framing matters as much as the numbers. Management's decision to accelerate investments in medical-cost management, provider connectivity and Carelon's integrated solutions suggests the company is using current earnings capacity to fund a multi-year effort to return to double-digit growth in 2027, effectively trading near-term earnings quality for a longer-term Margin thesis. The risk is that membership attrition across Medicare Advantage, Medicaid and Employer Group risk businesses continues longer than expected, delaying that recovery.

Outlook

Elevance's dividend remains well covered by Cash Flow despite the underlying earnings softness, though sustained dividend growth will depend on whether the company's targeted investments translate into the reaffirmed 12% adjusted EPS growth for 2027. Investors should watch membership trends by product line, benefit expense ratio trajectory, Carelon's contribution to operating gain and progress toward the 2027 growth target.

On a headline basis yes, but the beat was flattered by a one-time $0.80 per share investment benefit; excluding that, adjusted EPS fell 15.7% year over year.

Currently framed as near-term and anticipated. Management attributes the decline to expected ACA, Medicaid and Employer Group attrition alongside a fee-based customer transition, not a broader competitive loss.

Successful execution of current cost-management and Carelon investments. Management is explicitly trading near-term earnings quality for capabilities it expects will support at least 12% adjusted EPS growth in 2027.